Clinical trial · Interventional
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
NCT00988312CI-TRIAL-00002686completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Plasmocytoma | Plasmacytoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous idiotype-protein pulsed dendritic cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- s.c. vaccination
- description
- vaccine given subcutaneously
- interventionNames
- Biological: autologous idiotype-protein pulsed dendritic cells
- type
- EXPERIMENTAL
- label
- i.v. vaccination
- description
- vaccines are given intravenously
- interventionNames
- Biological: autologous idiotype-protein pulsed dendritic cells
Primary outcomes (1)
- measure
- Specific T-cell proliferation/cytokine secretion
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * multiple myeloma * stage I (Salmon \& Durie) * no cytoreductive pre-treatment Exclusion Criteria: * myeloma stages II-III * asecretory disease
References
Publications (0)
Data not yet available
No reference posted for this study.